Fabienne Brenet

CRCN INSERM

See the publications See the mail Tel : 04 86 97 72 85

Team

Signaling, Hematopoiesis and Mechanism of Oncogenesis

May 2014 Haematologica

SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.

Hanssens K, Brenet F, Agopian J, Georgin-Lavialle S, Damaj G, Cabaret L, Chandesris MO, de Sepulveda P, Hermine O, Dubreuil P, Soucie E

May 2014 Immunology and allergy clinics of North America

Molecular defects in mastocytosis: KIT and beyond KIT.

Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O, Damaj G, Dubreuil P, Arock M

Jan 2015 Molecular immunology

Molecular basis of mast cell disease.

Soucie E, Brenet F, Dubreuil P

Dec 2016 Annals of hematology

Familial hematological malignancies: new IDH2 mutation.

Hamadou WS, Bourdon V, Létard S, Brenet F, Laarif S, Besbes S, Paci A, David M, Penard-Lacronique V, Youssef YB, Laatiri MA, Eisinger F, Mari V, Gesta P, Dreyfus H, Bonadona V, Dugast C, Zattara H, Faivre L, Noguchi T, Khélif A, Salem CB, Dubreuil P, Sobol H, Soua Z

Jul 2015 Molecular & cellular oncology

Cutting the brakes on hematopoietic regeneration by blocking TGFβ to limit chemotherapy-induced myelosuppression.

Brenet F, Scandura JM

Nov 2013 Medecine sciences : M/S

[TGFβ contribution to hematopoietic regeneration after myelosuppressive chemotherapy].

Brenet F, Scandura JM

See all the publications